


PHARMACEUTICAL 2023

ARDELYX INC. Rank 236 of 446









PHARMACEUTICAL 2023

ARDELYX INC. Rank 236 of 446



The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 25% points. The greatest weakness of ARDELYX INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 72%, being 29% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	153,603
Cost of Goods Sold	4,117
Intangible Assets	0
Liabilities, Current	65,603
Liabilities, Non-Current	14,880
Other Assets	35,240
Other Compr. Net Income	-48
Other Expenses	5,081
Other Liabilities	11,254
Other Net Income	1,633
Other Revenues	52,158
Property and Equipment	1,223
Research and Development	35,201
Selling, General and Administrative Expense	76,599

Output Variable	Value in 1000 USD
Assets	190,066
Liabilities	91,737
Expenses	120,998
Revenues	52,158
Stockholders Equity	98,329
Net Income	-67,207
Comprehensive Net Income	-67,231
Economic Capital Ratio	72%

